» Articles » PMID: 29416611

Three-dimensional Tumor Model Mimics Stromal - Breast Cancer Cells Signaling

Overview
Journal Oncotarget
Specialty Oncology
Date 2018 Feb 9
PMID 29416611
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor stroma is a major contributor to the biological aggressiveness of cancer cells. Cancer cells induce activation of normal fibroblasts to carcinoma-associated fibroblasts (CAFs), which promote survival, proliferation, metastasis, and drug resistance of cancer cells. A better understanding of these interactions could lead to new, targeted therapies for cancers with limited treatment options, such as triple negative breast cancer (TNBC). To overcome limitations of standard monolayer cell cultures and xenograft models that lack tumor complexity and/or human stroma, we have developed a high throughput tumor spheroid technology utilizing a polymeric aqueous two-phase system to conveniently model interactions of CAFs and TNBC cells and quantify effects on signaling and drug resistance of cancer cells. We focused on signaling by chemokine CXCL12, a hallmark molecule secreted by CAFs, and receptor CXCR4, a driver of tumor progression and metastasis in TNBC. Using three-dimensional stromal-TNBC cells cultures, we demonstrate that CXCL12 - CXCR4 signaling significantly increases growth of TNBC cells and drug resistance through activation of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Despite resistance to standard chemotherapy, upregulation of MAPK and PI3K signaling sensitizes TNBC cells in co-culture spheroids to specific inhibitors of these kinase pathways. Furthermore, disrupting CXCL12 - CXCR4 signaling diminishes drug resistance of TNBC cells in co-culture spheroid models. This work illustrates the capability to identify mechanisms of drug resistance and overcome them using our engineered model of tumor-stromal interactions.

Citing Articles

Three-Dimensional Tumor Models to Study Cancer Stemness-Mediated Drug Resistance.

Lamichhane A, Tavana H Cell Mol Bioeng. 2024; 17(2):107-119.

PMID: 38737455 PMC: 11082110. DOI: 10.1007/s12195-024-00798-y.


A ten long noncoding RNA-based prognostic risk model construction and mechanism study in the basal-like immune-suppressed subtype of triple-negative breast cancer.

Huang X, Huang J, Huang Q, Zhou S Transl Cancer Res. 2024; 12(12):3653-3671.

PMID: 38193005 PMC: 10774046. DOI: 10.21037/tcr-23-147.


Mapping Cell-in-Cell Structures in Oral Squamous Cell Carcinoma.

Siquara da Rocha L, Souza B, Coletta R, Lambert D, Gurgel Rocha C Cells. 2023; 12(19).

PMID: 37830632 PMC: 10572403. DOI: 10.3390/cells12192418.


Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells.

Lamichhane A, Luker G, Agarwal S, Tavana H Oncotarget. 2023; 14:879-889.

PMID: 37791907 PMC: 10549774. DOI: 10.18632/oncotarget.28517.


Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches.

Lucic I, Kurtovic M, Mlinaric M, Pitesa N, cipak Gasparovic A, Sabol M Int J Mol Sci. 2023; 24(13).

PMID: 37445860 PMC: 10342190. DOI: 10.3390/ijms241310683.


References
1.
Olumi A, Grossfeld G, Hayward S, Carroll P, Tlsty T, Cunha G . Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999; 59(19):5002-11. PMC: 3300837. DOI: 10.1186/bcr138. View

2.
Kunz-Schughart L . Multicellular tumor spheroids: intermediates between monolayer culture and in vivo tumor. Cell Biol Int. 1999; 23(3):157-61. DOI: 10.1006/cbir.1999.0384. View

3.
Lohr M, Schmidt C, Ringel J, Kluth M, Muller P, Nizze H . Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 2001; 61(2):550-5. View

4.
Kunz-Schughart L, Heyder P, Schroeder J, Knuechel R . A heterologous 3-D coculture model of breast tumor cells and fibroblasts to study tumor-associated fibroblast differentiation. Exp Cell Res. 2001; 266(1):74-86. DOI: 10.1006/excr.2001.5210. View

5.
Blum J, Dieras V, Lo Russo P, Horton J, Rutman O, Buzdar A . Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001; 92(7):1759-68. DOI: 10.1002/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a. View